Empower Your Asthma Management with Cinqair

Cinqair, featuring reslizumab, is a breakthrough treatment for severe asthma in adults with an eosinophilic phenotype. Administered via intravenous infusion, Cinqair exerts its therapeutic effect by inhibiting the production and survival of eosinophils, thus mitigating airway inflammation and asthma symptoms.

Unlocking the Potential of Cinqair

As a prescription medication available at all Infuse One centers, Cinqair offers a targeted approach to managing severe asthma, providing relief and enhancing the quality of life for patients grappling with this chronic condition.

Understanding Cinqair’s Role

Reslizumab, the active ingredient in Cinqair, effectively targets eosinophils, the culprits behind airway inflammation and asthma exacerbations. By reducing eosinophil levels, Cinqair helps alleviate asthma symptoms and minimize the risk of asthma attacks.

Cinqair Infusion Dosage and Procedure

Patients undergo reslizumab administration through intravenous infusion. Typically, a Cinqair infusion session, conducted at medical facilities like Infuse One, spans a duration of 20 to 50 minutes.

Dosage and Treatment Schedule

The standard dosage regimen for Cinqair entails administering 3 mg/kg once every four weeks, ensuring consistent therapeutic benefits for patients managing severe asthma.

Procedure for Administering Cinqair via IV Infusion

During the infusion process, a nurse initiates by sterilizing the patient’s arm with rubbing alcohol to ensure a hygienic environment for IV needle insertion. Following this, the nurse secures the IV line in place using tape and connects it to the medication bag for seamless administration.

Optimizing Cinqair Infusion Therapy

During a Cinqair infusion session, patients typically spend between 20 and 50 minutes receiving treatment. The recommended dosage regimen entails a dose of 3 mg/kg administered intravenously once every four weeks, ensuring consistent and effective asthma management.

Navigating Potential Side Effects

While side effects with Cinqair are relatively uncommon, patients should remain vigilant for any adverse reactions, including cough, difficulty swallowing, dizziness, or skin rash. Prompt reporting of symptoms ensures timely intervention and appropriate management.

Preparing for a Cinqair Infusion

Before a Cinqair infusion, patients should inform their physician of any existing medical conditions, such as cancer or parasitic infections, and disclose their current medication regimen, including oral or inhaled corticosteroids. Adequate rest, hydration, and nutrition before treatment optimize the infusion experience.

Securing Your Cinqair Referral

Accessing Cinqair infusion therapy requires a physician’s order accompanied by comprehensive patient information and clinical documentation supporting the diagnosis of severe asthma with an eosinophilic phenotype. Essential components include lab results demonstrating elevated eosinophil levels and FEV1 test results.

Empower Your Journey with Cinqair

Cinqair offers a transformative solution for individuals living with severe asthma, providing relief and restoring control over their respiratory health. Consult with your healthcare provider today to explore how Cinqair infusion therapy can redefine your asthma management strategy and enhance your overall well-being.